JP2015514062A - Ｅ−カドヘリンの細胞外ドメインの阻害剤を含む併用療法 - Google Patents

Ｅ−カドヘリンの細胞外ドメインの阻害剤を含む併用療法 Download PDF

Info

Publication number
JP2015514062A
JP2015514062A JP2015500673A JP2015500673A JP2015514062A JP 2015514062 A JP2015514062 A JP 2015514062A JP 2015500673 A JP2015500673 A JP 2015500673A JP 2015500673 A JP2015500673 A JP 2015500673A JP 2015514062 A JP2015514062 A JP 2015514062A
Authority
JP
Japan
Prior art keywords
secad
agent
cancer
cadherin
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015500673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514062A5 (enExample
Inventor
ブロクソン，サビーネ
キルカニデス，ステファノス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of JP2015514062A publication Critical patent/JP2015514062A/ja
Publication of JP2015514062A5 publication Critical patent/JP2015514062A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2015500673A 2012-03-15 2013-03-15 Ｅ−カドヘリンの細胞外ドメインの阻害剤を含む併用療法 Pending JP2015514062A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261611390P 2012-03-15 2012-03-15
US61/611,390 2012-03-15
US201261736475P 2012-12-12 2012-12-12
US61/736,475 2012-12-12
PCT/US2013/032656 WO2013138790A1 (en) 2012-03-15 2013-03-15 Combination therapies including inhibitors of the extracellular domain of e-cadherin

Publications (2)

Publication Number Publication Date
JP2015514062A true JP2015514062A (ja) 2015-05-18
JP2015514062A5 JP2015514062A5 (enExample) 2016-05-12

Family

ID=49161879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015500673A Pending JP2015514062A (ja) 2012-03-15 2013-03-15 Ｅ−カドヘリンの細胞外ドメインの阻害剤を含む併用療法

Country Status (8)

Country Link
US (2) US20150037354A1 (enExample)
EP (1) EP2844270A4 (enExample)
JP (1) JP2015514062A (enExample)
KR (1) KR20140138956A (enExample)
CN (1) CN104519899A (enExample)
CA (1) CA2867456A1 (enExample)
RU (1) RU2014141114A (enExample)
WO (1) WO2013138790A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2895623B1 (en) 2012-09-17 2018-08-22 Agios Pharmaceuticals, Inc. Use of e-cadherin and vimentin for selection of treatment responsive patients
EP2922832B1 (en) 2012-11-21 2019-10-09 Agios Pharmaceuticals, Inc. Glutaminase inhibitors and methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
BR112016021620A2 (pt) 2014-03-21 2018-07-10 Agios Pharmaceuticals Inc compostos e seus métodos de uso
ES2732925T3 (es) * 2014-07-18 2019-11-26 Sanofi Sa Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer
CN111208283B (zh) * 2018-11-21 2023-09-26 中国科学院分子细胞科学卓越创新中心 增效的肿瘤抑制组合物及其应用
CN115040695B (zh) * 2021-03-09 2023-10-13 南开大学 一种基于VE-cad-Fc/N-cad-Fc的融合蛋白活性界面的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500862A (ja) * 2010-10-27 2014-01-16 ザ リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク Ｅ−カドヘリンの可溶性細胞外ドメインを標的とする組成物および癌治療のための関連方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT414097B (de) * 2004-06-25 2006-09-15 Petzelbauer Peter Dr Pharmazeutische zubereitung zur behandlung von schock
CN102753579A (zh) * 2009-05-01 2012-10-24 国立大学法人东京大学 抗钙粘着蛋白抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500862A (ja) * 2010-10-27 2014-01-16 ザ リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク Ｅ−カドヘリンの可溶性細胞外ドメインを標的とする組成物および癌治療のための関連方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J.MAMMARY GLAND BIOL.NEOPLASIA, vol. 13, JPN6017007303, 2008, pages 485 - 498, ISSN: 0003511899 *
ONCOGENE, vol. 28, JPN6017007300, 2009, pages 1206 - 1217, ISSN: 0003511898 *

Also Published As

Publication number Publication date
EP2844270A4 (en) 2016-01-27
US20190008957A1 (en) 2019-01-10
CA2867456A1 (en) 2013-09-19
CN104519899A (zh) 2015-04-15
KR20140138956A (ko) 2014-12-04
EP2844270A1 (en) 2015-03-11
US20150037354A1 (en) 2015-02-05
RU2014141114A (ru) 2016-05-10
WO2013138790A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
US20210380671A1 (en) Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
RU2765410C2 (ru) Способы лечения рака, включающие связывающие tigit агенты
CN103275227B (zh) Axl抗体
CN109369808B (zh) 用于治疗ror1癌症并抑制转移的抗体和疫苗
US20190008957A1 (en) Combination therapies including inhibitors of the extracellular domain of e-cadherin
HK1204950A1 (en) Binding agents that modulate the hippo pathway and uses thereof
CN110944665B (zh) 用于预防或治疗肺癌的amhrii结合化合物
JP2022512744A (ja) 肉腫様腎臓がんのための診断および治療方法
WO2023227115A1 (en) A method of treating solid tumor
AU2013231846A1 (en) Combination therapies including inhibitors of the extracellular domain of E-cadherin
KR20250158056A (ko) 이중특이성 항-egfr/c-met 항체 및 항-pd-1 항체를 사용한 병용 요법
HK40005045B (zh) 用於治疗ror1癌症并抑制转移的抗体和疫苗
HK40053242A (en) Diagnostic and therapeutic methods for sarcomatoid kidney cancer
HK1194681A (en) Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
HK40018953A (en) Diagnostic and therapeutic methods for cancer

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170307

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171017